Nayab Asim
Introduction
Diabetes, arthritis, cancer, and dementia are complex diseases influenced by genetic and environmental factors (1). Understanding these interactions can help researchers identify genes, tissues, and biological pathways involved in disease development.
A landmark study by Klein et al. in 2005 compared genetic variation in individuals with age-related macular degeneration (AMD) and controls. The researchers identified an association between AMD risk and variants in the CFH gene, which encodes complement factor H, a protein involved in regulating the complement system and immune responses. This finding demonstrated how genome-wide comparisons can identify genetic associations that help researchers investigate disease mechanisms (2).
Genome-wide association studies (GWAS) contribute to medical innovation by identifying genetic variants associated with disease, improving understanding of disease biology, informing drug-target discovery, and supporting genetic risk prediction. However, an association is an important starting point rather than proof that a variant causes disease or can be used directly in clinical practice (1,3).
How GWAS Is Conducted
Thousands of GWAS have investigated associations between genetic variants and a wide range of human traits and diseases. Polygenic risk scores (PRS) combine information from multiple genetic variants to estimate an individual’s genetic predisposition to conditions such as coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer (3).
Many complex diseases are influenced by numerous genetic variants, each of which may have a small effect on risk. Their combined effects, together with environmental, lifestyle, and other factors, contribute to an individual’s overall susceptibility to disease.
A typical GWAS begins with DNA samples from individuals with the condition or trait of interest and an appropriate comparison group. Participants are commonly genotyped using genetic microarrays, with statistical imputation used to estimate additional variants based on reference panels. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) can also be used in sequencing-based association studies, particularly when investigating rare variants or coding variation. Quality-control procedures are applied to samples and genetic data before statistical tests are performed to identify variants associated with the trait (3).
Findings can be compared across independent cohorts and replicated in additional populations to assess their reliability and generalisability. Subsequent analyses may include fine-mapping associated regions, identifying candidate genes, investigating gene function, examining biological pathways, and assessing genetic correlations between traits. Together, these approaches help researchers investigate the genetic architecture of diseases and evaluate the potential value of genetic findings for risk prediction and therapeutic development (3,4).

Figure 1: General workflow for conducting GWAS to investigate genetic associations with human traits and diseases. Image credit: Uffelmann et al. (3).
Case Studies
Cardiovascular Disease
Cardiovascular disease is a leading cause of death worldwide, and inflammation contributes to atherosclerotic cardiovascular disease. Genetic and functional research has implicated interleukin-6 (IL-6) signalling in cardiovascular disease, making this pathway a potential target for therapeutic intervention (5).
A 2025 study by Zhang et al. investigated genetic variants in the region surrounding IL6, the gene encoding interleukin-6. The researchers analysed data from a GWAS involving 575,531 individuals of European ancestry, examining variants within 300 kilobases upstream and downstream of IL6 that were associated with C-reactive protein (CRP), a marker of inflammation (6).
The researchers constructed a genetic instrument designed to mimic reduced IL-6 signalling, similar to the action of the anti-IL-6 antibody ziltivekimab. Their analyses associated genetically reduced IL-6 signalling with lower risks of coronary artery disease, peripheral artery disease, and atherosclerotic ischaemic stroke. However, the association with ischaemic stroke was not statistically significant in the UK Biobank one-sample analysis (6). The study also investigated safety-related outcomes and reported associations that differed from those previously observed with genetic instruments targeting IL-6 receptor signalling (6).
These findings provide genetic evidence supporting further investigation of IL-6 inhibition as a potential therapeutic strategy. However, genetic analyses that predict the effects of modifying a biological pathway do not, by themselves, establish the efficacy or safety of a drug in clinical practice. Clinical trials are needed to determine whether pharmacological inhibition produces the expected benefits and risks in patients.
Type 2 Diabetes
Type 2 diabetes is a complex disease influenced by genetic susceptibility, environmental exposures, and lifestyle factors. GWAS have identified numerous variants associated with diabetes risk and helped researchers investigate the biological mechanisms underlying the disease (4).
Some associated variants occur in regulatory regions, including active enhancers in pancreatic islet cells, which help control gene expression and insulin secretion (7). Other findings have implicated genes involved in zinc transport and pancreatic beta-cell function.
For example, loss-of-function variants in SLC30A8, which encodes the zinc transporter ZnT8, have been associated with reduced type 2 diabetes risk. A study involving approximately 150,000 individuals across five ancestry groups found that carriers of protein-truncating variants in SLC30A8 had a 65% lower risk of type 2 diabetes than non-carriers (8). This finding has generated interest in whether inhibiting ZnT8 could offer a therapeutic approach to diabetes prevention. However, translating a genetic finding into a safe and effective treatment requires further functional and clinical validation.
GWAS can also help researchers investigate differences in genetic risk between populations. Some variants occur at different frequencies across ancestral populations, and their observed effects may vary because of differences in genetic background, environmental exposures, study design, and other factors. Studying more diverse populations can improve understanding of disease biology and help researchers assess whether genetic risk prediction tools and potential treatments are applicable across different groups (4,9).
Limitations
GWAS have identified genetic associations with a wide range of traits. For example, large-scale studies have identified thousands of variants associated with human height (4). Polygenic risk scores may improve risk prediction for certain conditions, but their performance varies by disease and population. Their value must be assessed against existing clinical risk models and in relation to the specific clinical decisions they are intended to inform (9,10).
Several challenges remain in translating GWAS findings into clinical practice. Genetic associations do not necessarily identify causal variants or establish the biological mechanisms through which they act. Associated variants may be correlated with causal variants through linkage disequilibrium, and the relevant gene or mechanism may not be immediately apparent. Fine-mapping, functional experiments, and independent validation may therefore be needed to establish causality and determine whether a finding has therapeutic or diagnostic relevance (3,4).
The incorporation of genomic findings into clinical tools also requires continued development and evaluation. Identifying an individual’s genetic variants does not automatically establish the appropriate treatment. Clinical decisions require evidence that genetic information improves diagnosis, risk assessment, treatment selection, or patient outcomes (9,10).
Another important limitation is the under-representation of many populations in genomic research. A substantial proportion of GWAS data has historically come from individuals of European ancestry. This imbalance can limit the transferability of genetic risk scores to other populations and restrict the discovery of variants and biological mechanisms relevant to under-represented groups. Expanding research across populations in Africa, Asia, South America, and elsewhere is important for developing more representative genomic evidence and improving the applicability of personalised medicine (9,10).
Future Directions
Advances in sequencing technology have expanded access to genomic analysis and large-scale genetic research. Continued progress in statistical methods, computational approaches, and artificial intelligence (AI) may further improve the interpretation of complex genomic datasets (3,10).
Integrating genomic data with phenomic, transcriptomic, and proteomic information could help researchers connect genetic variants with observable traits, gene expression, protein activity, tissues, and biological pathways. These approaches may provide a more comprehensive understanding of disease mechanisms and help prioritise potential therapeutic targets (4,10).
However, the clinical value of these integrated approaches will depend on the quality and representativeness of the data, the reliability of analytical methods, independent validation, and evidence that the resulting insights improve patient care. AI-assisted analyses and multiomics integration can generate hypotheses and prioritise candidates, but they do not replace experimental investigation or clinical validation.

Figure 2: Potential clinical applications of GWAS and polygenic risk scores for estimating genetic predisposition to multifactorial diseases. Image credit: Zhang et al. (11).
Conclusion
GWAS have transformed the identification of genetic variants associated with human traits and diseases, contributing to research into disease mechanisms, genetic risk prediction, and drug discovery (4,11). Their findings can inform the development of diagnostic tools and personalised treatment strategies, but translating genetic associations into clinical benefits requires additional evidence.
Functional studies, statistical validation, and, where appropriate, in vitro and in vivo experiments are needed to investigate causal mechanisms and assess potential therapeutic targets. Clinical studies must then establish whether resulting interventions are effective and safe. Tools that integrate genetic, molecular, and phenotypic information may help researchers prioritise promising targets and investigate differences in treatment response.
GWAS may also contribute to understanding why patients respond differently to the same treatment. Genetic variation is one possible source of this heterogeneity, although treatment outcomes and clinical trial results are influenced by many factors.
The principal strength of GWAS lies in identifying genetic associations at scale. When combined with robust statistical analysis, functional investigation, and appropriate clinical validation, GWAS can make a substantial contribution to biomedical research and the continuing development of personalised medicine.
References
-
Southam L, Zeggini E. Twenty years of genome-wide association studies. Nature. 2025;641(8061):47–49. doi:10.1038/d41586-025-01128-6.
-
Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389. doi:10.1126/science.1109557.
-
Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. Nature Reviews Methods Primers. 2021;1:59. doi:10.1038/s43586-021-00056-9.
-
Visscher PM, Wray NR, Zhang Q, et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. American Journal of Human Genetics. 2017;101(1):5–22. doi:10.1016/j.ajhg.2017.06.005.
-
Su JH, Luo MY, Liang N, et al. Interleukin-6: A novel target for cardio-cerebrovascular diseases. Frontiers in Pharmacology. 2021;12:745061.
-
Zhang L, Omarov M, Xu L, et al. IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk. Nature Cardiovascular Research. 2025;4(9):1172–1186. doi:10.1038/s44161-025-00700-7.
-
Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nature Genetics. 2014;46(2):136–143. doi:10.1038/ng.2870.
-
Flannick J, Thorleifsson G, Beer NL, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nature Genetics. 2014;46(4):357–363. doi:10.1038/ng.2915.
-
Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics. 2019;51:584–591. doi:10.1038/s41588-019-0379-x.
-
Huang J, McLean GR, Franke A. Twenty years of genome-wide association studies: Health translation challenges and AI opportunities. European Journal of Human Genetics. 2025;33(12):1579–1584. doi:10.1038/s41431-025-01951-5.
-
Zhang W, Koslowski S, Benzaki M, et al. Deconstructing the GWAS library: next-generation GWAS. Physiological Reviews. 2025;105(4):2413–2448. doi:10.1152/physrev.00025.2024.